Revolution Medicines, Inc. Warrant
Revolution Medicines, Inc. Warrant
Your view on RVMDW
Overview
What the company does, where it operates, and who runs it.
About Revolution Medicines, Inc. Warrant
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Mark A. Goldsmith
- Headquarters
- 700 Saginaw Drive, Redwood City, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Mark A. Goldsmith
- Headquarters
- 700 Saginaw Drive, Redwood City, CA, US
Revolution Medicines, Inc. is a biopharmaceutical company in the clinical development phase, concentrating on creating innovative, precisely targeted therapies for cancers driven by RAS pathway dysregulation.
The firm's drug development portfolio features both RAS(ON) inhibitors, which are designed for potential use as single agents, in conjunction with other RAS(ON) inhibitors, or alongside RAS companion inhibitors and various therapeutic compounds.
Additionally, its pipeline includes dedicated RAS companion inhibitors intended for synergistic treatment approaches. Among its RAS(ON) inhibitors currently in Phase 1 clinical trials are RMC-6236 (targeting a broad spectrum of RAS mutations), RMC-6291 (specific to G12C), and RMC-9805 (for G12D).
Further compounds in preclinical or early development include RMC-5127 (for G12V), RMC-0708 (for Q61H), and RMC-8839 (for G13C), along with ongoing programs focused on G12R and other distinct molecular targets.
In the realm of RAS companion inhibitors, RMC-4630 is advancing through Phase 2 clinical assessment, while RMC-5552 is undergoing Phase 1 evaluation. Revolution Medicines, Inc. was founded in 2014 and operates from its headquarters in Redwood City, California.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Revolution Medicines, Inc. Warrant, and the rating behind it. RVMDW last traded at $10.76; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Revolution Medicines, Inc. Warrant. Starting points for Revolution Medicines, Inc. Warrant: EPS -$8.38, beta 1.40 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Revolution Medicines, Inc. Warrant. Revolution Medicines, Inc. Warrant does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Revolution Medicines, Inc. Warrant. Trailing twelve-month EPS for Revolution Medicines, Inc. Warrant stands at -$8.38. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Revolution Medicines, Inc. Warrant. Revolution Medicines, Inc. Warrant has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Revolution Medicines, Inc. Warrant valued side by side against its closest peers. Revolution Medicines, Inc. Warrant is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Revolution Medicines, Inc. Warrant, and how their positions are changing. At a $42.24B market value, institutional positions materially move Revolution Medicines, Inc. Warrant's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Revolution Medicines, Inc. Warrant executives and directors. Shares of Revolution Medicines, Inc. Warrant have traded between $0.39 and $11.50 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Revolution Medicines, Inc. Warrant. Revolution Medicines, Inc. Warrant is a $42.24B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Revolution Medicines, Inc. Warrant. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Revolution Medicines, Inc. Warrant. Coverage tracks Revolution Medicines, Inc. Warrant within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.